Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.42 |
| ▸ | GLRB | P48167 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621088 | 0.84 | POLB (0.48) | GLRA3GLRBALDH1A1CYP2C9TYR | |
| SCHEMBL2254157 | 0.81 | KDM4E (0.42) | GLRA3GLRBALDH1A1ALOX15LMNA | |
| SCHEMBL4806822 | 0.78 | VCAM1 (0.41) | GLRA3GLRBALDH1A1HSD17B10POLB | |
| SCHEMBL68860 | 0.76 | CYP2C9 (0.48) | GLRA3GLRBALDH1A1ALOX15LMNA | |
| Propionic Acid SCHEMBL1535102 | 0.76 | GLRA3 (0.52) | GLRA3GLRBALDH1A1ALOX15LMNA | |
| SCHEMBL30885859 | 0.76 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNANR1I2CYP2C9 | |
| SCHEMBL4630314 | 0.76 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNANR1I2CYP2C9 | |
| SCHEMBL9067390 | 0.74 | ALDH1A1 (0.39) | GLRA3GLRBALDH1A1ALOX15LMNA | |
| SCHEMBL2679857 | 0.74 | ALDH1A1 (0.46) | GLRA3GLRBALDH1A1ALOX15LMNA | |
| SCHEMBL27877808 | 0.74 | ALDH1A1 (0.46) | GLRA3GLRBALDH1A1ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | NANOPHARMACEUTICALS, LLC | 2015-01-29 | — | — | US | disclosed |
| US-8859539-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | GLRA3 453/4885GLRB 803/4885ALDH1A1 3152/4885 |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | GLRA3 453/4885GLRB 803/4885ALDH1A1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.